Early trial of targeted combo for rare breast cancer subtype ends early
Disease control
Terminated
This early-phase study tested a new drug (infigratinib) combined with tamoxifen for people with a specific advanced breast cancer that is hormone receptor-positive, HER2-negative, and has changes in the FGFR gene. The main goal was to find a safe dose by monitoring side effects. …
Phase: PHASE1 • Sponsor: Jennifer Lee Caswell-Jin • Aim: Disease control
Last updated May 06, 2026 16:03 UTC